Pricing and Access Archives

Blog

Rise with the Waves: Germany – A Tale of Two High Impact Policies Shaping Pharma’s Future

February 26, 2024

Executive Summary Multiple cost-containment reforms, such as the introduction of a 20% rebate on brand-brand combinations and a temporary increase in the mandatory rebate on drugs to 12%, were implemented under Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz)...

Blog

Priced Out: Generic Therapy Price Competition and Drug Shortages

January 29, 2024

Introduction In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be...

Blog

Key Takeaways and Learnings from ISPOR Europe 2023

December 7, 2023

Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both...

Blog

The Implementation Game: The Inflation Reduction Act Medicare Drug Price Negotiation Program Guidance

July 27, 2023

Trinity’s Take Introduction Since the Inflation Reduction Act (IRA) was signed into law in August 2022, biopharma stakeholders have noted the high likelihood of the legislation being challenged in court alongside many questions about how some of the new CMS programs...

money for medicine, within injection needle

Blog

The Future of AI for Market Access: An ISPOR US 2023 Recap

July 17, 2023

This year Trinity team members at ISPOR 2023 attended several symposia and presentations on the use of Artificial Intelligence (AI) to support biopharma evidence generation. Among many industry trends, experts anticipate that AI and machine learning will increasingly be leveraged to...

Worktable with computer, digital brain and globe superimposed

Blog

Inflation Reduction Act (IRA): ISPOR Key Takeaways

July 10, 2023

While attending the ISPOR US 2023 conference in Boston this year, Trinity team members had the opportunity to connect with industry colleagues, present original research, and participate in research panels and discussions regarding key industry trends. One top-of-mind industry topic for...

Blog

ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?

June 21, 2023

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team presenting at ISPOR 2023

Blog

The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future

April 21, 2023

Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...

Blog

Inflation Reduction Act of 2022: No Room for Negotiation

August 12, 2022

Long-awaited Medicare price negotiations look more like statuary discounts than the value-based negotiations seen in global healthcare systems; combined with expanded price increase rebates and out of pocket limits, new regulation may drive prices for new drugs up more than down....